looking back!!, page-12

re: to renee from pheenom re:article Here are the facts ,comments etc.that will be
in the article Sirtex Medical SRX on ASX
Revenues up 105 % ytd
Profits up 87 % sequentially from last qtr
Last year March qtr 2.0 million with excellent earnings comparison coming this qtr.
USA hospital growth 28 to 62 centers over 100 % growth in most profitable centers
New Australian government reimbursement of 24 more hospitals and growing
New upgrades to buy ;Bioshares strong buy, Huntleys, Macquarie
2008-2009 EPS estimate 72 cents, P.E of 4.2 x 2008-2009 , growing 100%+ , very undervalued compared to peer group with PEG of .04 compared to similar biotechs with PEG's of 2+
New clinical trials andnew chemo drugs expanding indications and revenues for Sir Spheres
FDA approved so offlabel usage already available for physiciansto expad usage
Insiders control 85 % of float with chairman invested 50 million of net worth in co.
Previous bid two years ago rejected of $4.85 so company fully evaluated by major US biotech co Cephalon as good investment
Well known pharmas Pfizer, and Aventis-Sanofi sponsoring product and newer chemotherapy drugs expanding synergistic usage of Sir Spheres and chemo drugs.
Company worth more than previous bid to an acquirer than two years ago as now firmly entrenched in US market,profitable, and 100% growth
Very profitable at treating only 0.5 % of eligible patients and with only penetrance of 5-8% for treating radiation oncologists room for salot of profit growth
New symposium on ongoing basis for radiation oncologists will lead to more rapid uptake of US growth
European reimbursement coming in short term
Technical chart broke up after long basing period with short term potential gain of 66-80% from current sp
Longer term large upside due toeither rapid growth based on conservative 20xP.E of 2008-2009 earnings =20x.72+$14.40, or acquisition value of $10-13
Nasdaq listing will increase sp as pool of US investors became aware of company as an undervalued biotech
My opinion only . Do your own work